SIK2 and ovarian neoplasm: Herein, we intended to develop a “smart” kinase‐triggered gel‐to‐solution transition strategy for local delivery and controlled release of SIK2 inhibitors at ovarian tumor sites to efficiently inhibit proliferation and metastasis of the tumor.